Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells 7,879 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 7,879 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $348,330.59. Following the transaction, the chief operating officer now directly owns 18,672 shares of the company’s stock, valued at $825,489.12. This represents a 29.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Peter Radovich also recently made the following trade(s):

• On Monday, February 3rd, Peter Radovich sold 2,627 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $48.22, for a total transaction of $126,673.94.
• On Friday, January 24th, Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total transaction of $152,241.84.
• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total transaction of $85,554.36.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM traded down $0.84 during trading hours on Tuesday, hitting $44.31. The stock had a trading volume of 350,774 shares, compared to its average volume of 513,013. The company has a 50 day simple moving average of $47.55 and a two-hundred day simple moving average of $43.60. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $54.23. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -21.94 and a beta of 1.04.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. Research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on MIRM. HC Wainwright raised their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $58.20.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MIRM. Lord Abbett & CO. LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at $28,913,000. Loomis Sayles & Co. L P purchased a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at $19,473,000. State Street Corp raised its position in shares of Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after buying an additional 297,511 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at $10,136,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at $10,611,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.